Moderna stock jumps 50% as Merck cancer vaccine trial succeeds

Moderna stock (MRNA) enters a pivotal moment. The daily chart remains firmly bullish, while intraday timeframes show a brief pullback. On August 19, positive Phase 3 INTerpath-001 results from Moderna and Merck triggered headlines of a 50% surge, a move far beyond the latest technical snapshot.

MRNA — daily chart with candlesticks, EMA20/EMA50 and volume.

Key takeaways

• The daily chart stays bullish, with the August 18 close of 62.96 above the EMA20, EMA50, and EMA200.
• Daily RSI14 sits at 55.04, leaving room before overbought conditions.
• The 1H MACD has turned negative, signaling a short-term pullback into the close.
• On August 19, Moderna and Merck reported positive INTerpath-001 Phase 3 results, with headlines describing a 50% surge.
• Daily resistance starts near 64.18, with the upper Bollinger Band at 65.39.

Moderna Stock Daily Trend: Structure Still Favors the Bulls

The daily trend for Moderna stock remains clearly bullish. On August 18, the close of 62.96 sat above the EMA20 at 60.74, the EMA50 at 59.54, and the EMA200 at 49.29. That stacked alignment is a textbook uptrend signature: shorter-term averages above longer-term ones, with the 200-day EMA far below current price. It reflects the strong six-month advance already noted in recent coverage of Moderna shares climbing 44.2% and touching 63.36.

Momentum on the daily chart supports the trend. RSI14 stands at 55.04, comfortably in bullish territory but nowhere near overbought. That leaves room for further upside without immediate exhaustion risk. The MACD line at 0.59 sits above its signal line at -0.33, producing a positive histogram of 0.92. In practical terms, momentum has been building steadily, not fading.

Volatility and levels tell a consistent story. The Bollinger Bands show a midline of 58.38, an upper band at 65.39, and a lower band at 51.37. Price trades in the upper half of that range but not yet at the top band. ATR14 at 3.76 confirms real daily swing potential, which matters given the news catalyst now in play. The daily pivot point sits at 63.15, with resistance at 64.18 and support at 61.94. That places the last close just below the pivot, essentially at a decision point.

1H Timeframe: Momentum Cools, But Trend Isn’t Broken

The hourly trend for Moderna stock is not broken, but momentum has cooled. Price at 62.95 has slipped below the EMA20 of 63.64, while remaining above the EMA50 at 62.35 and the EMA200 at 61.09. In other words, the shorter hourly average has been breached, but the broader intraday trend structure stays intact.

RSI14 on the 1H chart reads 46.62, a neutral level reflecting the pause rather than aggressive selling. However, the MACD tells a more pointed story. The MACD line at 0.25 has dropped below the signal line at 0.51, producing a negative histogram of -0.26. That crossover shows hourly momentum has turned down, consistent with a pullback after the prior run higher. The hourly pivot at 63.24 has price trading just beneath it, near support at 62.46. This lines up with buyers stepping back into consolidation into the close.

15m Execution Context: Short-Term Weakness Near Support

The 15-minute chart for Moderna stock shows short-term weakness near support. Notably, this is mostly execution-level noise relative to the daily trend. Price at 62.95 sits below both the EMA20 at 63.57 and the EMA50 at 63.71, while staying above the EMA200 at 62.10. RSI14 has dropped to 38.49, approaching oversold territory and signaling that short-term selling pressure picked up into the last session.

Meanwhile, the MACD on this timeframe is essentially flat. The line at -0.12 sits just under the signal at -0.11, with a histogram of -0.01. This near-zero reading suggests momentum has stalled rather than accelerated lower. Bollinger Bands show price near the lower band at 62.71, versus a midline of 63.49. This reinforces the idea of a short-term dip rather than a breakdown. The 15-minute pivot at 63.09 and support at 62.61 mark the immediate battleground. Intraday traders are watching for a bounce or a further slide.

The News Overlay: A Catalyst the Charts Haven’t Priced In Yet

The August 19 news catalyst has not been priced into the technical snapshot. All of the readings above are based on the August 18 daily close and the following hourly and 15-minute snapshots. On August 19, before the next daily candle could be captured, Moderna and Merck released positive topline results from the INTerpath-001 trial. It is a milestone for the mRNA-based personalized cancer vaccine platform.

Coverage from CNBC and Bloomberg described the reaction in Moderna stock as a 50% surge. That scale of move dwarfs the modest hourly and 15-minute pullback visible in the data. Therefore, the short-term weakness flagged on the 1H and 15m charts should be read with caution. It predates a catalyst capable of resetting the entire technical picture.

Bullish Scenario

The bullish case for Moderna stock rests on the daily trend remaining the dominant force. Buying interest fueled by the INTerpath-001 results could push price convincingly through the daily pivot at 63.15 and then resistance at 64.18. In that case, the next technical magnet becomes the upper Bollinger Band at 65.39.

At the same time, a reclaim of the hourly EMA20 at 63.64 would confirm the short-term pullback has ended. A recovery in the hourly MACD back above its signal line would signal fresh momentum taking over. Given the daily RSI of 55.04, there is room for the rally to extend without hitting overbought exhaustion immediately. This supports continuation rather than a quick fade.

Bearish Scenario

On the other hand, the bearish case would require the initial catalyst-driven enthusiasm to fade quickly. If price fails to hold above the daily EMA20 at 60.74 and slips back toward S1 support at 61.94, the picture would shift. The pullback visible on the 1H and 15m charts would then look less like consolidation and more like genuine distribution.

A break below the 15-minute lower Bollinger Band near 62.71 would strengthen the case for a deeper retracement. RSI14 pushing further under 38.49 into oversold territory would add to that pressure. In that scenario, the daily bullish regime would still technically hold above the EMA50 at 59.54. However, the momentum backing it would clearly be weakening.

Closing Take

Overall, the technical structure into August 18 favored the bulls. The daily trend was intact and momentum supportive, even as the hourly and 15-minute charts showed a short-term cooling phase. Meanwhile, the INTerpath-001 trial results reported on August 19 represent a catalyst large enough to override that near-term technical noise entirely.

Given the daily ATR14 of 3.76 and the scale of the reported price reaction, volatility around Moderna stock is likely to remain elevated in the sessions ahead. Positioning around these levels should account for that uncertainty. The gap between the last technical snapshot and the unfolding news flow is unusually wide right now.

FAQ

What does the daily chart say about Moderna stock?

The daily chart remains bullish. The August 18 close of 62.96 sits above the EMA20 at 60.74, the EMA50 at 59.54, and the EMA200 at 49.29. RSI14 at 55.04 leaves room before overbought conditions.

What news drove the 50% surge in Moderna stock?

On August 19, Moderna and Merck reported positive Phase 3 INTerpath-001 topline results. The trial tested intismeran autogene alongside Keytruda in resected melanoma and met its endpoints for recurrence-free survival and distant metastasis-free survival.

What are the key resistance levels to watch?

The daily pivot sits at 63.15, with resistance at 64.18. Above that, the upper Bollinger Band at 65.39 becomes the next technical magnet.

What would invalidate the bullish case?

A failure to hold above the daily EMA20 at 60.74 and a slip back toward support at 61.94 would suggest the pullback is becoming genuine distribution rather than consolidation.

Disclaimer: This article is for informational purposes only and does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell any financial instrument or cryptocurrency. The analysis provided is not indicative of future results. Investing in crypto assets and financial markets carries a high risk of capital loss. Always do your own research (DYOR) and consult a qualified financial advisor before making any decision.

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.